No headlines found.
Business Wire (Mon, 22-Jun 5:03 PM ET)
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
Kardigan trades on the NASDAQ stock market under the symbol KARD.
As of June 26, 2026, KARD stock price climbed to $22.61 with 128,827 million shares trading.
KARD has a market cap of $2.02 billion. This is considered a Mid Cap stock.
The top ETF exchange traded funds that KARD belongs to (by Net Assets): GSC, GDOC.
KARD support price is $20.71 and resistance is $24.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KARD shares will trade within this expected range on the day.
